Lung Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
DAM10 and DAM6, expressed in adult testis and lung tumors.
|
8535061 |
1995 |
Carcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
We isolated a transcript, MAGE Xp-2, by screening a cDNA library from the human epithelial carcinoma cell line, HEp-2, using autoantibodies from patients with systemic lupus erythematosus (SLE).
|
9538511 |
1998 |
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
We isolated a transcript, MAGE Xp-2, by screening a cDNA library from the human epithelial carcinoma cell line, HEp-2, using autoantibodies from patients with systemic lupus erythematosus (SLE).
|
9538511 |
1998 |
melanoma
|
0.020 |
AlteredExpression
|
disease |
LHGDN |
Hypertonicity induction of melanoma antigen, a tumor-associated antigen.
|
12018852 |
2002 |
Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Among the other MAGE family members only MAGEB2 and -C1 and the broadly expressed MAGED1, -D2, -F1 and -H1 were expressed in RCC.
|
16082191 |
2005 |
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Among the other MAGE family members only MAGEB2 and -C1 and the broadly expressed MAGED1, -D2, -F1 and -H1 were expressed in RCC.
|
16082191 |
2005 |
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Since the expression of CTA genes is usually very low or absent in myeloid leukemias, we treated various AML cell lines with 5-aza-2'-deoxycytidine (DAC) and quantified mRNA expression of the CTAs NY-ESO-1, MAGEA1, MAGEA3 and MAGEB2.
|
20381863 |
2010 |
Myeloid Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Since the expression of CTA genes is usually very low or absent in myeloid leukemias, we treated various AML cell lines with 5-aza-2'-deoxycytidine (DAC) and quantified mRNA expression of the CTAs NY-ESO-1, MAGEA1, MAGEA3 and MAGEB2.
|
20381863 |
2010 |
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified MAGEB2 as having significant promoter demethylation in primary head and neck squamous cell carcinoma tissues.
|
23029077 |
2012 |
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
SPANX-CD (71.9%), MAGEB2 (44.9%), MAGEA1 (44.9%), MAGEB6 (32.6%), and CXORF48 (27.0%) were found frequently expressed in HNSCC, and over 85% of the tumors expressed at least one of these five CTAs.
|
25564441 |
2015 |
melanoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Vaccination against MAGEB2 induced higher frequency of MAGEB2-specific CTL and exerted higher protective effect against melanoma development in mice bearing the CC AIRE genotype than in those bearing the TT one (p < 0.05).
|
27563821 |
2016 |
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Although cancer-testis antigens, including MAGEB2, are potential therapeutic targets for cancer in medical practice, information on MAGEB2 in MPNST is scarce.
|
26642794 |
2016 |
Neurofibromatosis 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The purpose is to clarify the methylation status and expression of MAGEB2 in MPNSTs derived from patients with NF-1.
|
26642794 |
2016 |
Malignant Peripheral Nerve Sheath Tumor
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RT-MSP and RT-PCR data showed low methylation levels and detectable mRNA expression of MAGEB2, respectively, in one MPNST cell line, but high methylation level and absence of expression in each other cell line and in normal cells.
|
26642794 |
2016 |
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Although cancer-testis antigens, including MAGEB2, are potential therapeutic targets for cancer in medical practice, information on MAGEB2 in MPNST is scarce.
|
26642794 |
2016 |